/Revvity%20Inc_%20logo%20on%20phone%20and%20site%20by-%20T_Schneier%20via%20Shutterstock.jpg)
Revvity, Inc. (RVTY), headquartered in Waltham, Massachusetts, is a leading provider of health sciences solutions, technologies, and diagnostic services. Valued at $14.7 billion by market cap, the company focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection, diagnosis, informatics, and other areas. The leading research and diagnostic firm is expected to announce its fiscal fourth-quarter earnings for 2024 before the market opens on Friday, Jan. 31.
Ahead of the event, analysts expect RVTY to report a profit of $1.36 per share on a diluted basis, up 8.8% from $1.25 per share in the year-ago quarter. The company has consistently surpassed Wall Street’s EPS estimates in its last four quarterly reports.